Michael B Atkins

发表

The promise of Immuno-oncology: implications for defining the value of cancer treatment

Prasun Subedi, Richard L Schilsky, James Wu, 2019, Journal of Immunotherapy for Cancer.

Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.

Michael B Atkins, P. Kantoff, S. Signoretti, 2013, The Lancet. Oncology.

Final version of 2009 AJCC melanoma staging and classification.

Jeffrey E Gershenwald, Merrick I Ross, Charles M Balch, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Wanling Xie, Tina Cheng, Michael B Atkins, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Resistance to targeted therapy in renal-cell carcinoma.

Michael B Atkins, M. Atkins, B. Rini, 2009, The Lancet. Oncology.

Defining the critical hurdles in cancer immunotherapy

Zhigang Tian, Sylvia Janetzki, Cedrik M Britten, 2011, Journal of Translational Medicine.

Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy.

S Nahum Goldberg, Jonathan B Kruskal, Michael B Atkins, 2008, AJR. American journal of roentgenology.

Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond

Michael B Atkins, Ryan J Sullivan, R. Sullivan, 2010, Expert opinion on investigational drugs.

Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference

Mark A Rosen, Michael B Atkins, Keith T Flaherty, 2007, Clinical Cancer Research.

Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma

Jon Richards, Michael B Atkins, M. Atkins, 2010, Clinical Cancer Research.

Management of cutaneous melanoma.

Michael B Atkins, Hensin Tsao, M. Atkins, 2004, The New England journal of medicine.

Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.

Ivan Pedrosa, A. D. Van den Abbeele, Annick D Van den Abbeele, 2011, European Urology.

Which drug, and when, for patients with BRAF-mutant melanoma?

Michael B Atkins, M. Atkins, S. Jang, 2013, The Lancet. Oncology.

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.

Donna Niedzwiecki, Edward L Korn, Michael B Atkins, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings.

Ivan Pedrosa, Neil M Rofsky, Michael B Atkins, 2009, Radiology.